MK-677 (ibutamoren) is an oral ghrelin mimetic that stimulates the body's own growth hormone release — used off-label for muscle gain, fat loss, bone density, and recovery.
What it does
MK-677 works by activating GHS-R1a, the ghrelin receptor — the same receptor targeted by injectable growth hormone secretagogues like GHRP-2 or ipamorelin. When this receptor fires, it triggers a Gq/PLC/calcium signaling cascade inside pituitary cells, prompting them to release growth hormone (GH). What makes MK-677 unusual is that it does this orally; every other compound in this class requires injection Junghun 2018.
Because MK-677 has a half-life of roughly six hours — with active metabolites persisting longer — it doesn't just produce a single sharp GH pulse the way injectable GHRPs do. Instead, it raises both the peak amplitude of GH pulses and the baseline (trough) GH level throughout the day. This translates into sustained elevation of IGF-1 (insulin-like growth factor 1, the liver-produced protein that carries out most of GH's tissue-building effects). A two-year controlled trial in elderly adults found this IGF-1 elevation held steady without tachyphylaxis — meaning the body did not adapt and stop responding — which is uncommon for compounds in this class Murphy 1998, PMID:10352464.
One mechanism worth flagging separately: because MK-677 mimics ghrelin, it activates ghrelin receptors not only in the pituitary but also in the gut and hypothalamus. This drives significant appetite stimulation — more pronounced than what most injectable secretagogues produce — and is a consistent feature users report Elder 2020.
What the evidence shows
Lean mass and body composition in older adults Multiple controlled trials in humans, mostly elderly populations; effect is real but modest
The most robust human data comes from elderly and sarcopenic (muscle-wasting) populations. Murphy et al. found that daily MK-677 increased lean body mass and improved bone density over 24 months without tolerance developing PubMed 10352464. A registered trial (NCT00474279) examined body composition and functional ability in older adults using the same endpoint. These aren't bodybuilder populations — they are older adults losing muscle with age — so extrapolating the magnitude of effect to younger, trained individuals requires caution.
Bone density Consistent signal in human trials, mostly elderly
The same two-year trial that tracked lean mass also showed measurable improvements in bone mineral density PubMed 10352464. This fits the known biology: sustained IGF-1 elevation stimulates osteoblasts (bone-building cells). The signal is real, but the population studied was elderly and osteopenic, so the clinical relevance for younger adults is less clear.
Chronic kidney disease and lean mass One registered trial, results limited
A registered trial (NCT01343641) investigated MK-677's effect on lean body mass in stage 4/5 chronic kidney disease patients, where muscle wasting is common. GHS-R1a receptors are expressed in kidney tissue and appear to influence renal hemodynamics (blood flow dynamics in the kidney) Elder 2020, which adds biological plausibility. Full results from this trial are not widely published.
Alzheimer's disease and neurogenesis Rodent data only; mixed results
Two mouse studies explored MK-677 in Alzheimer's models. One found improved neurogenesis (generation of new neurons) in the hippocampus but no protection against hippocampal lesions Jing 2019. A second found that ghrelin agonism reduced amyloid-beta pathology in a transgenic mouse model Yu-On 2018. This is early-stage rodent work — there are no human trials on cognition or Alzheimer's disease.
Nonalcoholic fatty liver disease (NAFLD) Active trial, no published results yet
A registered trial (NCT05364684) is examining ibutamoren's impact on NAFLD. The rationale involves GH's known role in hepatic fat metabolism. No results are available.
How it's used
In studies and self-reported protocols, doses range from 10 mg to 25 mg taken orally once daily. The 10 mg dose is the lower end used in some clinical trials; 25 mg was the standard dose in Murphy et al.'s two-year study PubMed 10352464. Most self-reported protocols favor bedtime dosing on the logic that it amplifies the natural GH pulse that occurs during deep sleep, and because the appetite stimulation is easier to manage overnight. MK-677 is taken daily rather than cyclically, consistent with its mechanism — intermittent use would not maintain the sustained IGF-1 elevation that characterizes its profile Junghun 2018.
Side effects and safety
The side effect profile is well-documented relative to most peptides because MK-677 has actual multi-year human trial data. Commonly reported effects include increased appetite, water retention, mild lethargy, and vivid dreams — these appear to be dose-dependent and partially attenuate over time. Joint swelling, numbness or tingling in the hands (consistent with carpal tunnel pressure from fluid), and transient muscle pain are reported at higher doses.
The most clinically significant concern is insulin resistance. MK-677 consistently raises fasting glucose and impairs insulin sensitivity across trials PubMed 10352464. This effect is not subtle — it is a pharmacological consequence of GH elevation, which is inherently anti-insulin. For anyone with pre-diabetes, metabolic syndrome, or a family history of type 2 diabetes, this is a meaningful risk. Uncontrolled diabetes is an absolute contraindication.
Fluid retention can be serious in people with heart failure or compromised cardiac function — edema risk is an absolute contraindication in that population. Because GH and IGF-1 can stimulate cell proliferation, active malignancy is also an absolute contraindication. Long-term data beyond two years in humans does not exist, and the effect on cancer risk over a decade of use is genuinely unknown.
Bottom line
MK-677 has more controlled human trial data than most compounds in the GH secretagogue category, and the evidence for lean mass and bone density in elderly populations is real. The trade-off is a consistent worsening of insulin sensitivity that makes it a poor fit for anyone with metabolic risk factors. For metabolically healthy individuals, it is a pharmacologically coherent option for sustained GH/IGF-1 elevation — but two years is the limit of available human safety data, and that gap matters.